{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:59:13Z","timestamp":1793235553614,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>The goal of this review is to evaluate the evolving role of triglycerides (TGs) and TG-rich lipoproteins (TRLs) in cardiovascular disease (CVD) risk and prevention. We examine the mechanistic rationale, genetic and epidemiological evidence, and therapeutic potential of targeting TGs in residual risk reduction, particularly in high-risk populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Emerging data from Mendelian randomization studies and large clinical cohorts support a causal link between elevated remnant lipoproteins and atherosclerotic CVD, in which apolipoprotein B may be the principal driver. Although traditional triglyceride-lowering agents have produced mixed results on cardiovascular outcomes, emerging therapies\u2014such as ApoC-III and ANGPTL3 inhibitors\u2014show robust lipid-lowering effects, while selective PPAR modulators have thus far not demonstrated cardiovascular benefit. However, outcome data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Residual CVD risk persists despite aggressive LDL-C reduction, especially in patients with diabetes, metabolic syndrome, or chronic kidney disease. Selective TG-lowering strategies targeting TRLs\u2014especially those that decrease apolipoprotein B\u2014may provide clinical benefit in high-risk phenotypes. Ongoing trials will clarify whether these promising agents confer meaningful cardiovascular protection and warrant integration into future guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-025-02337-1","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:38:34Z","timestamp":1767433114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies"],"prefix":"10.1007","volume":"28","author":[{"given":"Usman","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal V.","family":"Mathai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Filtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Sniderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"2337_CR1","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289\u201397. https:\/\/doi.org\/10.1001\/jama.2016.13985.","journal-title":"JAMA"},{"key":"2337_CR2","doi-asserted-by":"publisher","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","volume":"17","author":"TG Richardson","year":"2020","unstructured":"Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020;17:e1003062.","journal-title":"PLoS Med"},{"key":"2337_CR3","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","volume":"6","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Pletcher MJ, Vittinghoff E, Clemons AM, Jacobs DRJ, Allen NB, et al. Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events. JAMA Cardiol. 2021;6:1406\u201313.","journal-title":"JAMA Cardiol"},{"key":"2337_CR4","doi-asserted-by":"publisher","first-page":"106814","DOI":"10.1016\/j.phrs.2023.106814","volume":"193","author":"A Pirillo","year":"2023","unstructured":"Pirillo A, Norata GD. The burden of hypercholesterolemia and ischemic heart disease in an ageing world. Pharmacol Res. 2023;193:106814.","journal-title":"Pharmacol Res"},{"key":"2337_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","volume":"2","author":"JA Salami","year":"2017","unstructured":"Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2:56\u201365.","journal-title":"JAMA Cardiol"},{"key":"2337_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","volume":"368","author":"P Deedwania","year":"2006","unstructured":"Deedwania P, Barter P, Carmena R, Fruchart J-C, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006;368:919\u201328.","journal-title":"Lancet"},{"key":"2337_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1\u201310.","journal-title":"Curr Atheroscler Rep"},{"key":"2337_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547\u201363.","journal-title":"Circ Res"},{"key":"2337_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/ATVBAHA.116.307601","volume":"36","author":"R Puri","year":"2016","unstructured":"Puri R, Nissen SE, Shao M, Elshazly MB, Kataoka Y, Kapadia SR, et al. Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol. 2016;36:2220\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2337_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61:427\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"2337_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2147\/VHRM.S104369","volume":"12","author":"PP Toth","year":"2016","unstructured":"Toth PP. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. Vasc Health Risk Manag. 2016;12:171\u201383.","journal-title":"Vasc Health Risk Manag"},{"key":"2337_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364\u201373. https:\/\/doi.org\/10.1001\/jama.2018.20045.","journal-title":"JAMA"},{"key":"2337_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041382","author":"R Mszar","year":"2023","unstructured":"Mszar R, Bart S, Sakers A, Soffer D, Karalis DG. Current and emerging therapies for atherosclerotic cardiovascular disease risk reduction in hypertriglyceridemia. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12041382.","journal-title":"J Clin Med"},{"key":"2337_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-022-00676-y","volume":"19","author":"J Bor\u00e9n","year":"2022","unstructured":"Bor\u00e9n J, Taskinen M-R, Bj\u00f6rnson E, Packard CJ. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. Nat Rev Cardiol. 2022;19:577\u201392. https:\/\/doi.org\/10.1038\/s41569-022-00676-y.","journal-title":"Nat Rev Cardiol"},{"key":"2337_CR15","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42:4791\u2013806. https:\/\/doi.org\/10.1093\/eurheartj\/ehab551.","journal-title":"Eur Heart J"},{"key":"2337_CR16","unstructured":"16. Meeusen J, Ueda M, Nordestgaard B RA. Lipids and lipoproteins in Tietz Textbook of Laboratory Medicine. Elsevier Inc.; 2021."},{"key":"2337_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3389\/fendo.2020.00474","volume":"11","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen M-R. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 2020;11:474.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2337_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287\u201395.","journal-title":"JAMA Cardiol"},{"key":"2337_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","volume":"146","author":"E Hagstr\u00f6m","year":"2022","unstructured":"Hagstr\u00f6m E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, et al. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022;146:657\u201372.","journal-title":"Circulation"},{"key":"2337_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309\u201316.","journal-title":"JAMA."},{"key":"2337_CR21","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1017\/jns.2021.73","volume":"10","author":"BH Keirns","year":"2021","unstructured":"Keirns BH, Sciarrillo CM, Koemel NA, Emerson SR. Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk. J Nutr Sci. 2021;10:e75.","journal-title":"J Nutr Sci"},{"key":"2337_CR22","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","volume":"85","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard AT, Tybj\u00e6rg-Hansen A, Mansbach H, Kersten S, Nordestgaard BG, Rosenson RS. Target Populations for Novel Triglyceride-Lowering Therapies. J Am Coll Cardiol. 2025;85:1876\u201397.","journal-title":"J Am Coll Cardiol"},{"key":"2337_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jacl.2025.03.013","volume":"19","author":"F Javed","year":"2025","unstructured":"Javed F, Hegele RA, Garg A, Patni N, Gaudet D, Williams L, et al. Familial chylomicronemia syndrome: an expert clinical review from the National Lipid Association. J Clin Lipidol. 2025;19:382\u2013403. https:\/\/doi.org\/10.1016\/j.jacl.2025.03.013.","journal-title":"J Clin Lipidol"},{"key":"2337_CR24","doi-asserted-by":"crossref","unstructured":"Ueda M. Familial chylomicronemia syndrome: importance of diagnostic vigilance. Transl Pediatr China. 2022;1588\u201394.","DOI":"10.21037\/tp-22-488"},{"key":"2337_CR25","doi-asserted-by":"crossref","unstructured":"TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby J, Peloso GM et al. Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. N Engl J Med. 2014;371:22\u201331. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1307095","DOI":"10.1056\/NEJMoa1307095"},{"key":"2337_CR26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"E DF","year":"2025","unstructured":"DF E, Viktoria G, Colm O, Omri G, Jesus T, Charleen H, et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. N Engl J Med. 2025;374:1123\u201333. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1510926","journal-title":"N Engl J Med"},{"key":"2337_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45:1345\u201352.","journal-title":"Nat Genet"},{"key":"2337_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020459","author":"M Hermel","year":"2023","unstructured":"Hermel M, Lieberman M, Slipczuk L, Rana JS, Virani SS. Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15020459.","journal-title":"Pharmaceutics"},{"key":"2337_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2025.09.006","author":"MD Shapiro","year":"2025","unstructured":"Shapiro MD, Slipczuk L. APOC3 inhibition: the strongest case yet for triglyceride targeting. Prog Cardiovasc Dis. 2025. https:\/\/doi.org\/10.1016\/j.pcad.2025.09.006.","journal-title":"Prog Cardiovasc Dis"},{"key":"2337_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcmg.2021.10.017","volume":"15","author":"CA Miguel","year":"2022","unstructured":"Miguel C-A, Renato Q, Ramzi D, Philip G, Donald L-JSRJ, et al. CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC Cardiovasc Imaging. 2022;15:641\u201351. Available from: https:\/\/doi.org\/10.1016\/j.jcmg.2021.10.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"2337_CR31","doi-asserted-by":"publisher","first-page":"e014116","DOI":"10.1161\/CIRCIMAGING.122.014116","volume":"15","author":"Q-Y Hao","year":"2022","unstructured":"Hao Q-Y, Gao J-W, Yuan Z-M, Gao M, Wang J-F, Schiele F, et al. Remnant cholesterol and the risk of coronary artery calcium progression: insights from the CARDIA and MESA study. Circ Cardiovasc Imaging. 2022;15:e014116. https:\/\/doi.org\/10.1161\/CIRCIMAGING.122.014116.","journal-title":"Circ Cardiovasc Imaging"},{"key":"2337_CR32","doi-asserted-by":"crossref","unstructured":"H. MM, Sommer BM, R. MS, I.M. AR, R.S. SP, E. JC, et al. Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy. JACC Cardiovasc Imaging. 2019;12:1797\u2013804. Available from: https:\/\/doi.org\/10.1016\/j.jcmg.2018.09.019","DOI":"10.1016\/j.jcmg.2018.09.019"},{"key":"2337_CR33","doi-asserted-by":"publisher","first-page":"824470","DOI":"10.3389\/fcvm.2022.824470","volume":"9","author":"H Yamaura","year":"2022","unstructured":"Yamaura H, Otsuka K, Ishikawa H, Shirasawa K, Fukuda D, Kasayuki N. Determinants of non-calcified low-attenuation coronary plaque burden in patients without known coronary artery disease: a coronary CT angiography study. Front Cardiovasc Med. 2022;9:824470.","journal-title":"Front Cardiovasc Med"},{"key":"2337_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/ehjci\/jeu033","volume":"15","author":"AH Ellims","year":"2014","unstructured":"Ellims AH, Wong G, Weir JM, Lew P, Meikle PJ, Taylor AJ. Plasma lipidomic analysis predicts non-calcified coronary artery plaque in asymptomatic patients at intermediate risk of coronary artery disease. European Heart Journal - Cardiovascular Imaging. 2014;15:908\u201316. https:\/\/doi.org\/10.1093\/ehjci\/jeu033.","journal-title":"European Heart Journal - Cardiovascular Imaging"},{"key":"2337_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/2047487319887578","volume":"27","author":"MB Elshazly","year":"2020","unstructured":"Elshazly MB, Mani P, Nissen S, Brennan DM, Clark D, Martin S, et al. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol. 2020;27:1091\u2013100.","journal-title":"Eur J Prev Cardiol"},{"key":"2337_CR36","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","volume":"41","author":"MJ Budoff","year":"2020","unstructured":"Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925\u201332.","journal-title":"Eur Heart J"},{"key":"2337_CR37","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/ehjci\/jead063","volume":"24","author":"MG Rabbat","year":"2023","unstructured":"Rabbat MG, Lakshmanan S, Benjamin MM, Doros G, Kinninger A, Budoff MJ, et al. Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT. Eur Hear journal Cardiovasc Imaging. 2023;24:866\u201373.","journal-title":"Eur Hear journal Cardiovasc Imaging."},{"key":"2337_CR38","doi-asserted-by":"crossref","unstructured":"Ferrer R, Mansilla A, Tondo M, Blanco-Vaca F. Remnant cholesterol: new outcomes highlight its potential as a clinically useful cardiovascular risk factor. J Lab Precis Med 2023;8 Available from: https:\/\/jlpm.amegroups.org\/article\/view\/7650","DOI":"10.21037\/jlpm-22-70"},{"key":"2337_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312759","author":"B-Y Pan","year":"2024","unstructured":"Pan B-Y, Chen C-S, Chen F-Y, Shen M-Y. Multifaceted role of Apolipoprotein C3 in cardiovascular disease risk and metabolic disorder in diabetes. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252312759.","journal-title":"Int J Mol Sci"},{"key":"2337_CR40","doi-asserted-by":"publisher","first-page":"e008139","DOI":"10.1161\/JAHA.117.008139","volume":"7","author":"S LeBlanc","year":"2025","unstructured":"LeBlanc S, Coulombe F, Bertrand OF, Bibeau K, Pibarot P, Marette A, et al. Hypertriglyceridemic waist: a simple marker of high-risk atherosclerosis features associated with excess visceral adiposity\/ectopic Fat. J Am Heart Assoc. 2025;7:e008139. Available from: https:\/\/doi.org\/10.1161\/JAHA.117.008139","journal-title":"J Am Heart Assoc"},{"key":"2337_CR41","doi-asserted-by":"crossref","unstructured":"Kozakova M, Morizzo C, Penno G, Chiappino D, Palombo C. Diabetes-Related Changes in Carotid Wall Properties: Role of Triglycerides. J Clin Med. 2024;13.","DOI":"10.3390\/jcm13185654"},{"issue":"35","key":"2337_CR42","doi-asserted-by":"publisher","first-page":"ehaf411","DOI":"10.1093\/eurheartj\/ehaf411","volume":"46","author":"C Gurevitz","year":"2025","unstructured":"Gurevitz C, Bajaj A, Khera AV, Do R, Schunkert H, Musunuru K, et al. Gene therapy and genome editing for lipoprotein disorders. Eur Heart J. 2025;ehaf411. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf411.","journal-title":"Eur Heart J"},{"key":"2337_CR43","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702\u20135.","journal-title":"Science."},{"key":"2337_CR44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019;381:531\u201342.","journal-title":"N Engl J Med."},{"key":"2337_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold I, Alexander VJ, Yang Q, Hurh E, Steinhagen-Thiessen E, Moriarty PM, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:264\u201375.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2337_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1194\/jlr.M066399","volume":"57","author":"X Yang","year":"2016","unstructured":"Yang X, Lee S-R, Choi Y-S, Alexander VJ, Digenio A, Yang Q, et al. Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. J Lipid Res. 2016;57:706\u201313.","journal-title":"J Lipid Res"},{"key":"2337_CR47","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408\u201315. https:\/\/doi.org\/10.2337\/dc16-0126.","journal-title":"Diabetes Care"},{"key":"2337_CR48","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa2402309","volume":"390","author":"BA Bergmark","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024;390:1770\u201380.","journal-title":"N Engl J Med."},{"key":"2337_CR49","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2507227","volume":"393","author":"BA Bergmark","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med. 2025;393:1279\u201391.","journal-title":"N Engl J Med."},{"key":"2337_CR50","doi-asserted-by":"crossref","unstructured":"Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2025.","DOI":"10.1056\/NEJMoa2512761"},{"key":"2337_CR51","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9:620\u201330.","journal-title":"JAMA Cardiol."},{"key":"2337_CR52","volume":"2017","author":"M Hassan","year":"2017","unstructured":"Hassan M. ANGPLT3: A novel modulator of lipid metabolism. Glob Cardiol Sci Pract. 2017;2017: e201706.","journal-title":"Glob Cardiol Sci Pract."},{"key":"2337_CR53","doi-asserted-by":"crossref","unstructured":"RF J, S. RR, F. RL, Kees HG, J.P. KJ, Paolo R, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383:711\u201320. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2004215","DOI":"10.1056\/NEJMoa2004215"},{"key":"2337_CR54","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29:729\u201337.","journal-title":"Nat Med"},{"key":"2337_CR55","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10557-024-07567-z","volume":"39","author":"RS Rosenson","year":"2025","unstructured":"Rosenson RS, Rader DJ, Ali S, Banerjee P, McGinniss J, Pordy R. Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials. Cardiovasc drugs Ther. 2025;39:925\u201331.","journal-title":"Cardiovasc drugs Ther"},{"key":"2337_CR56","doi-asserted-by":"crossref","unstructured":"Rosenson RS, George RT, Sanchez RJ, Zhao X-Q, Ponda MP, Waldron A, et al. Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial. J Clin Lipidol. 2025;","DOI":"10.1016\/j.jacl.2025.07.005"},{"key":"2337_CR57","doi-asserted-by":"publisher","first-page":"e13836","DOI":"10.1111\/cts.13836","volume":"17","author":"R Dingman","year":"2024","unstructured":"Dingman R, Bihorel S, Gusarova V, Mendell J, Pordy R. Evinacumab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17:e13836. Available from: https:\/\/doi.org\/10.1111\/cts.13836","journal-title":"Clin Transl Sci"},{"key":"2337_CR58","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","volume":"41","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp LF, Millar JS, Wu L, Jansen H, van Harskamp D, Schierbeek H, et al. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2021;41:1753\u20139.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"2337_CR59","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts GF, Schwabe C, Scott R, Gladding PA, Sullivan D, Baker J, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023;29:2216\u201323. Available from: https:\/\/doi.org\/10.1038\/s41591-023-02494-2","journal-title":"Nat Med"},{"key":"2337_CR60","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","volume":"393","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Baker J, Sarraju A, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025;393:2119\u201330.","journal-title":"N Engl J Med."},{"key":"2337_CR61","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (London, England). 2005;366:1849\u201361.","journal-title":"Lancet (London, England)"},{"key":"2337_CR62","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med."},{"key":"2337_CR63","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12933-024-02305-z","volume":"23","author":"JC Fruchart","year":"2024","unstructured":"Fruchart J-C, Fruchart-Najib J, Yamashita S, Libby P, Yokote K, Kodama T, et al. Lessons from PROMINENT and prospects for pemafibrate. Cardiovasc Diabetol. 2024;23:279. Available from: https:\/\/doi.org\/10.1186\/s12933-024-02305-z","journal-title":"Cardiovasc Diabetol"},{"key":"2337_CR64","doi-asserted-by":"crossref","unstructured":"Aruna DP, J. GR, Jean-Charles F, G. MJ, S. ZE, M. EB, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387:1923\u201334. Available from: https:\/\/doi.org\/10.1056\/NEJMoa2210645","DOI":"10.1056\/NEJMoa2210645"},{"key":"2337_CR65","doi-asserted-by":"crossref","unstructured":"Virani SS. The Fibrates Story - A Tepid End to a PROMINENT Drug. N. Engl. J. Med. United States. 2022;1991\u20132.","DOI":"10.1056\/NEJMe2213208"},{"key":"2337_CR66","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","journal-title":"Circulation"},{"key":"2337_CR67","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","volume":"13","author":"CE Orringer","year":"2019","unstructured":"Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13:860\u201372.","journal-title":"J Clin Lipidol"},{"key":"2337_CR68","doi-asserted-by":"crossref","unstructured":"S. VS, B. MP, Anandita A, M. BC, K. BK, M. K-EP, et al. ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia. JACC. 2021;78:960\u201393. Available from: https:\/\/doi.org\/10.1016\/j.jacc.2021.06.011","DOI":"10.1016\/j.jacc.2021.06.011"},{"key":"2337_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"2337_CR70","doi-asserted-by":"publisher","first-page":"100978","DOI":"10.1016\/j.ajpc.2025.100978","volume":"22","author":"S Saadatagah","year":"2025","unstructured":"Saadatagah S, Larouche M, Naderian M, Nambi V, Brisson D, Kullo IJ, et al. Recognition and management of persistent chylomicronemia: a joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology. Am J Prev Cardiol. 2025;22:100978.","journal-title":"Am J Prev Cardiol"},{"key":"2337_CR71","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","volume":"176","author":"SB Pedersen","year":"2016","unstructured":"Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. 2016;176:1834\u201342.","journal-title":"JAMA Intern Med"},{"key":"2337_CR72","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337.","journal-title":"Eur Heart J"},{"key":"2337_CR73","doi-asserted-by":"crossref","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, Tokg\u00f6zo\u011flu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025.","DOI":"10.1093\/eurheartj\/ehaf919"},{"key":"2337_CR74","doi-asserted-by":"publisher","first-page":"1389106","DOI":"10.3389\/fcvm.2024.1389106","volume":"11","author":"B Bashir","year":"2024","unstructured":"Bashir B, Schofield J, Downie P, France M, Ashcroft DM, Wright AK, et al. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia. Front Cardiovasc Med. 2024;11:1389106.","journal-title":"Front Cardiovasc Med."},{"key":"2337_CR75","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med."},{"key":"2337_CR76","doi-asserted-by":"publisher","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","volume":"99","author":"JB Buse","year":"2007","unstructured":"Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:21i\u201333i.","journal-title":"Am J Cardiol."},{"key":"2337_CR77","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"HPS2-THRIVE Collaborative Group","year":"2013","unstructured":"HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279\u201391.","journal-title":"Eur Heart J"},{"key":"2337_CR78","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.ajpc.2024.100648","volume":"18","author":"A Filtz","year":"2024","unstructured":"Filtz A, Parihar S, Greenberg GS, Park CM, Scotti A, Lorenzatti D, et al. New approaches to triglyceride reduction: is there any hope left? Am J Prev Cardiol. 2024;18:100648.","journal-title":"Am J Prev Cardiol"},{"key":"2337_CR79","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacl.2023.05.101","volume":"17","author":"M Paquette","year":"2023","unstructured":"Paquette M, Blais C, Fortin A, Bernard S, Baass A. Dietary recommendations for dysbetalipoproteinemia: a need for better evidence. J Clin Lipidol. 2023;17:549\u201356.","journal-title":"J Clin Lipidol"},{"key":"2337_CR80","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrendo.2012.15","volume":"8","author":"MCGJ Brouwers","year":"2012","unstructured":"Brouwers MCGJ, van Greevenbroek MMJ, Stehouwer CDA, de Graaf J, Stalenhoef AFH. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol. 2012;8:352\u201362. https:\/\/doi.org\/10.1038\/nrendo.2012.15.","journal-title":"Nat Rev Endocrinol"},{"key":"2337_CR81","first-page":"224","volume":"70","author":"OY Bello-Chavolla","year":"2018","unstructured":"Bello-Chavolla OY, Kuri-Garc\u00eda A, R\u00edos-R\u00edos M, Vargas-V\u00e1zquez A, Cort\u00e9s-Arroyo JE, Tapia-Gonz\u00e1lez G, et al. Familial combined hyperlipidemia: current knowledge, perspectives and controversies. Rev Invest Clin. 2018;70:224\u201336.","journal-title":"Rev Invest Clin"},{"key":"2337_CR82","first-page":"1267","volume":"366","author":"C Baigent","year":"2024","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (London, England). 2005;366:1267\u201378.","journal-title":"Lancet (London, England)"},{"key":"2337_CR83","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","volume":"26","author":"A Keech","year":"2003","unstructured":"Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care. 2003;26:2713\u201321.","journal-title":"Diabetes Care"},{"key":"2337_CR84","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","volume":"51","author":"M Miller","year":"2008","unstructured":"Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724\u201330.","journal-title":"J Am Coll Cardiol"},{"key":"2337_CR85","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","volume":"138","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation. 2018;138:770\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032318.","journal-title":"Circulation"},{"key":"2337_CR86","doi-asserted-by":"crossref","unstructured":"Abdul Jabbar A Bin, Inam M, Butt N, Khan SS, Sheikh S, Khoja A, et al. Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations: What Clinicians Need to Know? Curr Atheroscler Rep. 2025;27:73.","DOI":"10.1007\/s11883-025-01320-z"},{"key":"2337_CR87","doi-asserted-by":"crossref","unstructured":"Miocardico GI per lo S della S nell\u2019Infarto. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto miocardico. Lancet (London, England). 1999;354:447\u201355.","DOI":"10.1016\/S0140-6736(99)07072-5"},{"key":"2337_CR88","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379:1540\u201350.","journal-title":"N Engl J Med."},{"key":"2337_CR89","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23\u201332.","journal-title":"N Engl J Med"},{"key":"2337_CR90","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1161\/CIRCULATIONAHA.120.052209","volume":"143","author":"AA Kalstad","year":"2021","unstructured":"Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. Circulation [Internet]. 2021;143:528\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052209.","journal-title":"Circulation [Internet]"},{"key":"2337_CR91","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"M Yokoyama","year":"2007","unstructured":"Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090\u20138.","journal-title":"Lancet"},{"key":"2337_CR92","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","volume":"150","author":"K Miyauchi","year":"2024","unstructured":"Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, et al. Randomized trial for evaluation in secondary prevention efficacy of combination therapy\u2013statin and eicosapentaenoic acid (RESPECT-EPA). Circulation. 2024;150:425\u201334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065520.","journal-title":"Circulation"},{"key":"2337_CR93","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Gabriel SP, Michael M, A. BE, A. JT, B. KS, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322. Available from: https:\/\/doi.org\/10.1056\/NEJMoa1812792","DOI":"10.1056\/NEJMoa1812792"},{"key":"2337_CR94","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","volume":"146","author":"PM Ridker","year":"2022","unstructured":"Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1\u03b2, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation. 2022;146:372\u20139.","journal-title":"Circulation"},{"key":"2337_CR95","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","volume":"41","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281\u20138.","journal-title":"Clin Cardiol"},{"key":"2337_CR96","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/HCO.0000000000001136","volume":"39","author":"M Miller","year":"2024","unstructured":"Miller M. Pemafibrate and other triglyceride-lowering therapies to reduce risk of cardiovascular and metabolic disease. Curr Opin Cardiol. 2024;39:286\u201391.","journal-title":"Curr Opin Cardiol"},{"key":"2337_CR97","unstructured":"U.S. Food and Drug Administration. FDA Clinical Review of Mineral Oil Effects in REDUCE-IT. 2019. Available from: https:\/\/downloads.regulations.gov\/FDA-2019-P-3156-0006\/attachment_1.pdf"},{"key":"2337_CR98","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.mayocp.2020.08.034","volume":"96","author":"AA Bernasconi","year":"2021","unstructured":"Bernasconi AA, Wiest MM, Lavie CJ, Milani RV, Laukkanen JA. Effect of omega-3 dosage on cardiovascular outcomes: an updated meta-analysis and meta-regression of interventional trials. Mayo Clin Proc. 2021;96:304\u201313. https:\/\/doi.org\/10.1016\/j.mayocp.2020.08.034.","journal-title":"Mayo Clin Proc"},{"key":"2337_CR99","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.mayocp.2021.03.004","volume":"96","author":"AA Bernasconi","year":"2021","unstructured":"Bernasconi AA, Lavie CJ, Milani RV, Laukkanen JA. Omega-3 benefits remain strong post-STRENGTH. Mayo Clin Proc. 2021;96:1371\u20132. https:\/\/doi.org\/10.1016\/j.mayocp.2021.03.004.","journal-title":"Mayo Clin Proc"},{"key":"2337_CR100","first-page":"e7\u20138","volume":"7","author":"SS Virani","year":"2021","unstructured":"Virani SS, Nambi V, Ballantyne CM. Has the \u201cstrength\u201d of fish oil therapy been \u201creduced\u201d? Reconciling the results of REDUCE-IT and STRENGTH. Eur Heart J. 2021;7:e7\u20138.","journal-title":"Eur Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02337-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:04:45Z","timestamp":1767477885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02337-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02337-1","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Virani has received research support from the NIH, US Department of Veterans Affairs, NIHR UK, Tahir and Jooma Family, and the Asharia Family foundations. Dr. Lavie has served as a consultant and speaker for GOED and DSM-Firmenich. Dr. Bhatt discloses the following relationships: Advisory Board: Angiowave, Antlia Bioscience, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, NirvaMed, Novo Nordisk, Repair Biotechnologies, Stasys, Tourmaline Bio; Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock); Consultant: Alnylam, Altimmune, Broadview Ventures, Corcept Therapeutics, Corsera, GlaxoSmithKline, Hims, SERB, SFJ, Summa Therapeutics, Worldwide Clinical Trials; Data Monitoring Committees: Acesion Pharma, Assistance Publique-H\u00f4pitaux de Paris, Baim Institute for Clinical Research, Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi\/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Duke Clinical Research Institute, Engage Health Media, HMP Global (Editor in Chief, Journal of Invasive Cardiology), Medtelligence\/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Philips (Becker's Webinar on AI), Population Health Research Institute, WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor); Progress in Cardiovascular Diseases (Deputy Editor); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent); Research Funding: Abbott, Acesion Pharma, Afimmune, Alnylam, Amarin, Amgen, AstraZeneca, Atricure, Bayer, Boehringer Ingelheim, Boston Scientific, CellProthera, Cereno Scientific, Chiesi, Cleerly, CSL Behring, Faraday Pharmaceuticals, Fractyl, Idorsia, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, MiRUS, Moderna, Novartis, Novo Nordisk, Pfizer, PhaseBio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, 89Bio; Royalties: Elsevier (Editor, Braunwald\u2019s Heart Disease); Site Co-Investigator: Cleerly. Dr Slipczuk discloses the following relationships: Honoraria: Elsevier\/Progress in Cardiovascular Diseases, Editor-in-Chief; Clinical trials: Site PI \u2013 Amgen and Philips; Grants: Past research funding Amgen and Philips. Dr. Toth reports the following disclosures: Speakers Bureau for Amgen; Consultant for Merck and Novartis. Dr. Shapiro reports the following disclosures: grants from DCRI, Esperion, Ionis, Merck, NHLBI, New Amsterdam, Novartis, and Amgen; personal fees from Amgen, Agepha, Novartis, and Ionis; and consultancy for Regeneron Pharmaceuticals, Inc., Ionis, Novartis, Aidoc, Shanghai Pharma Biotherapeutics, and Novo Nordisk, outside the submitted work. All other authors have no disclosures to report. Other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No animal or human subjects by the authors were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"8"}}